Mebendazole
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00643 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 17 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | acne (disease) | KG + DL |
| 2 | leishmaniasis, diffuse cutaneous | KG + DL |
| 3 | echinococcus granulosus infectious disease | KG + DL |
| 4 | hordeolum | KG + DL |
| 5 | alveolar echinococcosis | KG + DL |
| 6 | inhalational botulism | KG + DL |
| 7 | toxin-mediated infectious botulism | KG + DL |
| 8 | impetigo | KG + DL |
| 9 | Sorsby’s fundus dystrophy | KG + DL |
| 10 | demodicidosis of sebaceous gland | KG + DL |
| 11 | zinc, elevated plasma | KG + DL |
| 12 | mucocutaneous leishmaniasis | KG + DL |
| 13 | adult-onset citrullinemia type I | KG + DL |
| 14 | acute neonatal citrullinemia type I | KG + DL |
| 15 | squamous cell lung carcinoma | KG + DL |
| 16 | staphylococcal scalded skin syndrome | KG + DL |
| 17 | schistosomiasis | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.